Target Information

Target General Infomation
Target ID
T29143
Former ID
TTDC00177
Target Name
Interleukin-13
Gene Name
IL13
Synonyms
IL-13; IL13
Target Type
Clinical Trial
Disease Allergic asthma [ICD9: 493, 995.3; ICD10: J45, T78.4]
Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10: J00, J30, J31.0, T78.4]
Asthma; Ulcerative colitis [ICD10: J45, K51]
Allergy [ICD9: 995.3; ICD10: T78.4]
Asthma; Atopic eczema [ICD10: J45, L20-L30]
Asthma; Chronic obstructive pulmonary disease [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45]
Idiopathic pulmonary fibrosis [ICD9: 516.3; ICD10: J84.1]
Severe asthma [ICD9: 493; ICD10: J45]
Function
Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
BioChemical Class
Cytokine: interleukin
Target Validation
T29143
UniProt ID
P35225
Sequence
MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAP
LCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRD
TKIEVAQFVKDLLLHLKKLFREGRFN
Drugs and Mode of Action
Drug(s) Lebrikizumab Drug Info Phase 3 Severe asthma [524323], [542664]
Anrukinzumab Drug Info Phase 2 Asthma; Ulcerative colitis [521957], [889341], [889361]
Lebrikizumab Drug Info Phase 2 Asthma; Chronic obstructive pulmonary disease [889356], [889357], [889387], [889415]
PEGylated pitrakinra Drug Info Phase 2 Asthma; Atopic eczema [889352], [889354]
QAX-576 Drug Info Phase 2 Allergic rhinitis [523308]
SAR156597 Drug Info Phase 2 Idiopathic pulmonary fibrosis [889407]
CNTO-5825 Drug Info Phase 1 Allergic asthma [522965]
PEGylated pitrakinra Drug Info Investigative Allergy [889443]
Modulator Anrukinzumab Drug Info
Lebrikizumab Drug Info [889443]
PEGylated pitrakinra Drug Info [889443]
QAX-576 Drug Info [532959]
SAR156597 Drug Info [889442]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Fc epsilon RI signaling pathway
Measles
Asthma
Inflammatory bowel disease (IBD)
NetPath Pathway IL9 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
Leptin Signaling Pathway
TSLP Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Glucocorticoid receptor regulatory network
IL12 signaling mediated by STAT4
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
WikiPathways SIDS Susceptibility Pathways
Cytokines and Inflammatory Response
Allograft Rejection
References
Ref 521957ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health.
Ref 522965ClinicalTrials.gov (NCT01081691) A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers. U.S. National Institutes of Health.
Ref 523308ClinicalTrials.gov (NCT01266135) Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
Ref 524323ClinicalTrials.gov (NCT01875003) A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication. U.S. National Institutes of Health.
Ref 542664(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7684).
Ref 889341ClinicalTrials.gov (NCT00410280) Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Ref 889352ClinicalTrials.gov (NCT00676884) A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
Ref 889354ClinicalTrials.gov (NCT00801853) A Study of the Treatment-Sparing Effects of AEROVANT?AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL
Ref 889356ClinicalTrials.gov (NCT00930163) A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
Ref 889357ClinicalTrials.gov (NCT00971035) A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
Ref 889361ClinicalTrials.gov (NCT01284062) Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
Ref 889387ClinicalTrials.gov (NCT01987492) A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
Ref 889407ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Ref 889415ClinicalTrials.gov (NCT02546700) A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Ref 889443The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792.
Ref 532069Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
Ref 532959Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
Ref 889442Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.
Ref 889443The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.